Better Health for All

Arcellx is a clinical-stage biotechnology company entirely focused on developing novel cell therapies for severe, incurable diseases such as multiple myeloma, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), generalized myasthenia gravis, and solid tumors

. These conditions represent significant unmet medical needs, with 5-year survival rates of approximately 50% for multiple myeloma and 29% for AML . In a Phase 1 study, the company's CART-ddBCMA therapy showed a 100% overall response rate in 6 out of 6 evaluable patients with relapsed and refractory multiple myeloma , with 4 achieving stringent complete responses . The company's entire business is dedicated to the research and development of novel cell therapy platforms like ddCAR and ARC-SparX to enhance efficacy, reduce side effects, and improve accessibility of treatments . As a clinical-stage company, 100% of its capital allocation is directed towards health improvement, and it has no products on the market with negative health impacts. Arcellx provides information about its clinical trials on its website and clinicaltrials.gov , and transparently states that its investigational therapies have not yet been approved by regulatory authorities and their safety and efficacy have not been established .

Fair Money & Economic Opportunity

Arcellx, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for cancer and other incurable diseases

. The company's core business does not involve offering lending, deposit, or other financial services to consumers. Therefore, the KPIs related to fair money and economic opportunity, which are designed for financial institutions and their financial products, are not applicable to Arcellx's operations. While the company addresses populations with high medical need and conducts global clinical trials , these activities do not fall under the scope of financial inclusion or economic opportunity as defined by the rubric.

Fair Pay & Worker Respect

All employees and their families receive 100% health insurance premium coverage.

The company reports a voluntary attrition rate of under 5% in the past 12 months. Employee engagement data shows 97% positive reviews from 508 responses on Comparably, where the company has also received awards for culture, compensation, and work-life balance, and is Great Place to Work certified. There are no reported substantiated labor-law or human-rights violations. The CEO to median employee pay ratio was 79:1 in 2024. No employees are represented by a labor union or covered under a collective bargaining agreement. Glassdoor reviews, based on 31 responses, show an overall rating of 3.0 out of 5 stars, with specific concerns about work-life balance (2.9/5), diversity, equity & inclusion (2.9/5), and culture & values (3.0/5), including mentions of a "clicky" environment, nepotism, and favoritism. As of December 31, 2023, the workforce comprised 130 full-time employees, with 53% female and 68% diverse representation overall.

Honest & Fair Business

Arcellx has a Code of Business Conduct and Ethics, adopted January 13, 2022, which includes a "zero tolerance" policy strictly prohibiting all forms of bribery and corruption.

All covered persons must sign an acknowledgment form annually, confirming they have read this Code and that they understand and agree to comply with its provisions, both at the time of hire and annually thereafter. The Audit Committee annually reviews the overall adequacy and effectiveness of the company's legal, regulatory, and ethical compliance programs, including compliance with anti-bribery and anti-corruption laws. The company also has a comprehensive whistleblower policy. It does not permit retaliation for good faith reports of violations and provides procedures for confidential, anonymous submission of concerns regarding accounting or auditing matters. A 24/7 confidential reporting hotline, email, and mailing address are available for employees to report concerns. The Audit Committee oversees these complaint procedures.

Kind to Animals

Arcellx, Inc. has significant involvement in animal testing, conducting pre-clinical studies on animals to evaluate the safety profile of its product candidates

, . The company does not appear to be certified cruelty-free . There is no information provided regarding the company's use of alternative testing methods or details on its animal testing policies, including their scope or enforcement .

No War, No Weapons

Arcellx, Inc. has no military contracting and no controversial weapons, according to ESG data updated in July 2025.

The company's core business is focused on developing cell therapies for cancer, indicating no dual-use technology development or sales.

Planet-Friendly Business

No data relevant to ACLX.US's planet-friendly business practices, sustainability metrics, or environmental performance could be extracted from the provided articles. The articles primarily consist of governance document lists

, , , , job postings , or general information about data platforms , none of which contain specific quantitative data, regulatory actions, certifications, or initiatives related to environmental stewardship for the company.

Respect for Cultures & Communities

Arcellx, Inc. lacks specific quantitative data across all metrics related to respect for cultures and communities.

The provided articles do not mention formal partnerships with indigenous or local community groups, specific percentages of revenue reinvested in local community development, or any cultural appropriation incidents. There is no evidence of a formal cultural impact assessment protocol, FPIC processes, or specific cultural preservation investments. Similarly, data on local employment ratios, community-specific grievance mechanisms, local procurement, indigenous suppliers, cultural site protection, or social license to operate is absent. The company supports general community initiatives, such as the Multiple Myeloma Foundation's 5K run, and invests in patient support programs, with $10 million projected for 2024. However, no specific charitable giving to cultural heritage organizations is noted, nor is there a cultural incident response framework or cultural sensitivity training mentioned. Given the nature of a clinical-stage biotechnology company, many of these metrics are not directly applicable to its core operations.

Safe & Smart Tech

Arcellx extensively uses AI-powered discovery and computational tools, including machine learning algorithms for immunogenicity risk assessment and protein structure determination.

However, the company does not mention a formal AI ethics policy, dedicated oversight, or any AI/algorithm audit practices, despite its significant use of AI in potentially high-risk applications. The company has established policies and processes for managing cybersecurity threats, including an incident response plan and cyber insurance. It invests in state-of-the-art firewalls and intrusion detection systems, conducts regular security assessments (including penetration testing, vulnerability scanning, and third-party audits), and provides comprehensive cybersecurity training to all employees. Its cybersecurity processes also include patch management, endpoint detection and response, managed detection and response, data encryption, access control, and vulnerability management. Arcellx maintains reasonable technical, administrative, and organizational measures to protect personal information and states it will not retain data longer than reasonably necessary. Users are granted rights to access, correct, object to processing, request erasure, restrict processing, and transfer their personal information, with requests acknowledged within 5 days and completed within 30 days. The company states it complies with applicable laws and regulations. However, no specific privacy certifications or bug bounty programs are mentioned, and the company disclaims guarantees regarding the security of its site.